Skip to Content
Merck
All Photos(1)

Documents

SML1736

Sigma-Aldrich

Nelarabine

≥98% (HPLC)

Synonym(s):

2-amino-9-β-D-arabinofuranosyl-6-methoxy-9H-purine, 506U, 506U78, 9-β-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine, Arranon, Atriance, GW-506U78

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H15N5O5
CAS Number:
121032-29-9
Molecular Weight:
297.27
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

O[C@@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C=NC3=C2N=C(N)N=C3OC

InChI

1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10?/m1/s1

InChI key

IXOXBSCIXZEQEQ-KBNQYOMWSA-N

Biochem/physiol Actions

Nelarabine is an antineoplastic purine nucleoside analog used in T-cell acute lymphoblastic leukemia. It is a pro-drug of Ara-G, which is converted by cellular kinases to the active 5′-triphosphate, Ara-GTP. Incorporation of Ara-GTP into DNA leads to inhibition of DNA synthesis and apoptosis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Cytarabine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1787

Cytarabine

Luteolin ≥98% (TLC), powder

Sigma-Aldrich

L9283

Luteolin

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Marlise R Luskin et al.
British journal of haematology, 174(2), 332-334 (2015-09-26)
Larry W Buie et al.
Clinical therapeutics, 29(9), 1887-1899 (2007-11-24)
Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at
Stuart S Winter et al.
Pediatric blood & cancer, 62(7), 1176-1183 (2015-03-11)
Nelarabine has shown impressive single agent clinical activity in T-cell acute lymphoblastic leukemia (T-ALL), but has been associated with significant neurotoxicities in heavily pre-treated patients. We showed previously that it was safe to add nelarabine to a BFM-86 chemotherapy backbone

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service